Skip to main content
publicaciones

Scientific articles published by the researchers of Barcelonaβeta Brain Research Center (BBRC), related to Alzheimer's disease, neuroimaging, memory and neurodegenerative diseases, among other fields.

  • Blazhenets G, Soleimani-Meigooni DN, Chiotis K, Allen IE, Rabinovici GD, La Joie R; Meta-Centiloid Study Group; Apostolova LG, Asken BM, Bejanin A, Benzinger TLS, Betthauser TJ, Bluma M, Bombois S, Bourgeat P, Bouteloup V, Braskie MN, Brendel M, Brickman AM, Bryant N, Bullich S, Carrillo MC, Casaletto K, Cash DM, Chang CC, Chang HI, Chao Y, Chêne G, Chételat G, Coath W, Collij LE, Colmant L, Corrada MM, Craft S, Dickerson BC, Dubois B, Dufouil C, Fajardo A, Farrar G, Fortea J, Frings L, Frisoni GB, Gardner RC, Garibotto V, Gnörich JS, Gordon BA, Gu Y, Guan Y, Guo T, Hanseeuw BJ, Hansson O, Harrison TM, Huang Q, Huang SH, Iaccarino L, Ishii K, Ishi K, Jagust WJ, Johnson SC, Kato T, Katsumi Y, Kaye J, Koeppe RA, Kolinger GD, Kramer JH, Landau SM, Landeau B, Lao PJ, Lee S, Lleó A, Lopresti BJ, Lowe VJ, Luchsinger JA, Malpetti M, Mao X, March A, Masters CL, Meyer PT, Mezenge F, Mormino EC, Franquesa-Mullerat M, Nakamura A, Nordberg A, O'Brien JT, O'Bryant SE, Pappas I, Peretti DE, Quenon L, Rowe CC, Rowe JB, Rudolph MD, Salvadó G, Schott JM, Schwartz DL, Schwarz CG, Seo SW, Shekari M, Silbert LC, Smith R, Snyder HM, Sokolowski A, Sperling RA, Sun P, Taggett JZ, Toga AW, Touroutoglou A, Vaillancourt DE, van de Giessen E, Vijverberg J, Vemuri P, Villain N, Villemagne VL, Villeneuve S, Wang WE, Weiner M, Woodworth D, Xiao C, Xie F, Yoon Y, Young CB, Yun M; A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN, Severanc.

    Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis

    JAMA
    Abstract

    Importance: Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting...

  • Pelkmans W, Bikou V, Salvadó G.

    Timing the Alzheimer's disease pathological cascade

    Brain
  • Pieperhoff L, Lorenzini L, Almeida F, Tranfa M, Bollack A, Arunachalam P, Masserini F, Wolz R, Grootoonk S, Ritchie C, Boada M, Marquié M, Vijverberg J, Vandenberghe R, Hanseeuw BJ, Martinez-Lage P, Payoux P, Visser PJ, Schöll M, Frisoni GB, Pardini M, Roccataglia L, Stephens AW, Buckley C, Farrar G, Jessen F, Gispert JD, Salvadó G, Luckett ES, Mutsaerts HM, Wink AM, Collij LE, Barkhof F, Oliveira TG; AMYPAD consortium.

    Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia

    Alzheimer's & Dementia
    Abstract

    Introduction: Early Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than...

  • Gallay C, Soldevila-Domenech N, López-Martos D, Sanchez-Benávides G, Huguet J, Suárez-Calvet M, Gispert JD, Salvadó G, Sundermann EE, Grau-Rivera O, Brugulat-Serrat A; for ALFA study. 

    Effect of Parity and β-Amyloid on Cognition and Hippocampal Volume in Postmenopausal Women

    Neurology
    Abstract

    Background and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD...

  • López-Martos D, Suárez-Calvet M, Salvadó G, Cacciaglia R, Shekari M, González-Escalante A, Horta-Barba A, Palma-Gudiel H, Milà-Alomà M, Brugulat-Serrat A, Minguillon C, Tonietto M, Borroni E, Klein G, Quijano-Rubio C, Kollmorgen G, Zetterberg H, Blennow K, Gispert JD, Sánchez-Benavides G, Grau-Rivera O; ALFA study.

    Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    Neurobiology of Aging
    Abstract

    Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is...

  • Arunachalam P, Pieperhoff L, Lorenzini L, Tranfa M, Masserini F, Treves F, Pontillo G, Preti MG, Broeders TAA, Schoonheim MM, Douw L, Ritchie C, Boada M, Marquié M, Visser PJ, Cacciaglia R, Gispert JD, Salvadó G, Luckett ES, Collij LE, Cole JH, Barkhof F, Wink AM; AMYPAD consortium. 

    Decreased amyloid-related structure-function coupling in preclinical Alzheimer's disease

    Communications medicine
    Abstract

    Background: Structural pathways of the brain facilitate functional communication, and their disruption in preclinical Alzheimer's disease may reflect network vulnerability and compensatory brain...

  • López-Martos D, Cacciaglia R, Suárez-Calvet M, Salvadó G, Shekari M, González-Escalante A, Milà-Alomà M, Brugulat-Serrat A, Minguillon C, Tonietto M, Borroni E, Klein G, Quijano-Rubio C, Kollmorgen G, Zetterberg H, Blennow K, Gispert JD, Grau-Rivera O, Sánchez-Benavides G; ALFA study. 

    Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease.

    The journal of prevention of Alzheimer's Disease
    Abstract

    Background: The objective of this study was to provide a multimodal biomarker characterization of amnestic objective subtle cognitive decline (obj-SCD) in aging and preclinical Alzheimer's disease (AD...

  • Salvadó G, Horie K, Barthélemy NR, Schindler SE, Janelidze S, Orduña Dolado A, Bali D, Perrin RJ, Morris JC, Benzinger TLS, Gordon BA, Stomrud E, Mattsson-Carlgren N, Palmqvist S, Vogel JW, Bateman RJ, Ossenkoppele R, Hansson O

    Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease

    JAMA Neurology
    Abstract

    Importance: Biological staging of Alzheimer disease (AD) can improve diagnostic accuracy and prognostic assessment. However, existing approaches often require invasive procedures and specialized...

  • Shekari M, Escalante AG, Milà-Alomà M, Falcon C, López-Martos D, Sánchez-Benavides G, Brugulat-Serrat A, Niñerola-Baizán A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Montoliu-Gaya L, Snellman A, Day TA, Dage JL, Ortiz-Romero P, Tonietto M, Borroni E, Klein G, Kollmorgen G, Carboni M, Quijano-Rubio C, Vanmechelen E, Minguillón C, Fauria K, Perissinotti A, Molinuevo JL, Zetterberg H, Blennow K, Grau-Rivera O, Suárez-Calvet M, Gispert JD; ALFA Study.

    Associations of 18F-RO-948 tau PET with fluid AD biomarkers, Centiloid, and cognition in early AD continuum

    Alzheimer's & Dementia
    Abstract

    Introduction: We examined neurofibrillary tangle (NFT) pathology using 18F-RO-948 tau positron emission tomography (PET) in cognitively unimpaired individuals and its associations with amyloid plaques...

  • Mattsson-Carlgren N, Palmqvist S, Horie K, Barthélemy N, Salvadó G, Binette AP, Tideman P, Morris JC, Benzinger TL, Perrin RJ, Janelidze S, Collij LE, Ossenkoppele R, Schindler SE, Stomrud E, Bateman RJ, Hansson O.

    Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study

    The Lancet Neurology
    Abstract

    Background: Alzheimer's disease pathology can be accurately identified with blood biomarkers (core 1 biomarkers), including plasma p-tau217 tests. Biomarkers that change longitudinally after diagnosis...